By Nigel Somerville | Thursday 29 August 2019
Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.
Yesterday we learnt from Citywire that Neil Woodford has dumped his holding in Nasdaq-listed Prothena (PRTA) for £50 million to San Francisco-based biotech investor EcoR1 Capital, ending another disastrous tale of woe. In the early days of Woodford Investment Management this was a star investment and Neil chucked in piles of other people’s money but last year it ran into trouble when its flagship treatment for amyloidosis failed in trials. In the good old days Woodford’s holding topped well over £500 million in value – and he’s got just £50 million for his 22% stake...
Already registered? Click here to sign in
This area of the ShareProphets.com site is for independent financial commentary. These blogs are provided by independent authors via a common carrier platform and do not represent the opinions of ShareProphets.com. ShareProphets.com does not monitor, approve, endorse or exert editorial control over these articles and does not therefore accept responsibility for or make any warranties in connection with or recommend that you or any third party rely on such information. The information available at ShareProphets.com is for your general information and use and is not intended to address your particular requirements. In particular, the information does not constitute any form of advice or recommendation by ShareProphets.com and is not intended to be relied upon by users in making (or refraining from making) any investment decisions.
Search ShareProphets |
Stock market news |
Recent Comments |
Site by Everywhen